Corcept (CORT) Q3 2025 Earnings Call Transcript

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• SG&A expenses expected to increase in 2026 for relacorilant launches

  80% confidence

• Corcept has embarked on a mission to advance GR antagonism to help many patients with a broad range of solid tumors

  80% confidence

• Nenocorilant preclinical data expected public release in 2026

  80% confidence

• Authorized generic share expected to reach approximately 75% by year-end 2025

  80% confidence

• Phase III trial for dazucorilant in ALS planned for mid-2026 with design finalized with FDA and European regulators

  80% confidence

• ROSELLA final overall survival results expected early 2026

  80% confidence

• BELLA trial results expected by end of 2026

  80% confidence

• Immunotherapy market comprises over 200,000 patients in U.S. receiving treatment annually

  80% confidence

• CATALYST trial showed patients experienced improvements in body weight and waist circumference, even while decreasing or discontinuing GLP-1 agonists like Ozempic and Mounjaro

  80% confidence

• MOMENTUM hypertension trial results expected early 2026

  80% confidence

• No change in gross margin expected despite volume and mix shifts toward authorized generic

  80% confidence

• Patients who progressed on PARP inhibitors in ROSELLA trial showed profound benefit from relacorilant

  80% confidence

• Current addressable market is 20,000 patients with platinum-resistant ovarian cancer in U.S., expanding to 60,000 patients with new gynecological cancer studies

  80% confidence

• Corcept has 2 pharmacies: Optime Care continuing to service active patient base and Curant handling all new prescriptions

  80% confidence

• Goal is to extend ovarian cancer work in 3 ways: earlier lines of therapy, new types of solid tumors, and combining GR antagonist with additional regimens

  80% confidence

• MONARCH MASH trial results expected late 2026

  80% confidence

• Relacorilant will generate $3 billion to $5 billion in annual revenue in hypercortisolism alone within the next 3 to 5 years

  80% confidence

• R&D expenses expected to be flat year-over-year in 2026

  80% confidence

• Second specialty pharmacy to come online in January 2026, third pharmacy in early 2026

  80% confidence

• Approximately 60% of solid tumors express glucocorticoid receptor at all treatment stages

  80% confidence

Cited in these Via News reports

• China's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, Regeneron →
• Global Pharma Giants Redraw Strategic Maps as M&A Wave and Pipeline Milestones Reshape the Sector →